Aggressive HER2 amplified and ‘triple negative’ cancers (those without HER2 overamplification, oestrogen or progesterone receptor expression) demonstrate different patterns of metastatic disease, but there is as yet no convincing evidence for altering the strategy for staging according to tumour biology [6]. The gene discussed is ERBB2; the disease is cancer.